Pivotal trial data published in The New England Journal of Medicine supports the use of daptomycin in the treatment of bacteraemia and endocarditis caused by MRSA. The head-to-head study demonstrated daptomycin single agent therapy was as effective as dual agent comparator treatments and also has a favourable safety and tolerability profile with more creatine phosphokinase (CK) elevations but significantly fewer renal side effects reported versus comparator treatments.(2) The favourable safety profile is an important factor in severely ill patients.
A recent survey suggests that there is delay in patients receiving appropriate treatment for MRSA in approximately 50% of cases.(7) Delaying effective treatment for 48 hours can increase mortality as well as result in longer hospital stays, thus increasing the burden on the healthcare system.(8-11) Since Daptomycin is equally effective in treating MSSA and MRSA, it represents an important new empirical treatment choice for patients with MRSA bacteraemia associated with right sided endocarditis or complicated soft skin tissue infections.(2)
About the product
Daptomycin was first approved in the UK in March 2006 and received a positive Scottish Medicines Consortium (SMC) recommendation for its use in treating complicated skin and soft tissue infections (cSSTIs) in March 2006.
Last month, The Committee for Medical Products for Human Use (CHMP)
gave extended approval to daptomycin for the use in right-sided infective
endocarditis (RIE) due to Staphylococcus aureus an
|SOURCE Novartis Pharmaceuticals UK Ltd|
Copyright©2007 PR Newswire.
All rights reserved